Lovaltech develops protein‑based nasal vaccines that induce mucosal immunity to block infection at the entry point and reduce viral shedding. The needle‑free, room‑temperature‑stable formulation uses a muco‑adhesive excipient for easy, non‑invasive delivery, targeting public health agencies and vaccine manufacturers seeking scalable solutions for respiratory diseases.
Funding
$5.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current injectable vaccines primarily induce systemic immunity and often do not prevent infection or viral shedding at mucosal surfaces, leaving individuals vulnerable to transmission and limiting control of respiratory pathogens.
Solution
Lovaltech develops a protein-based nasal vaccine that targets the mucosal immune system to block infection at the entry point and reduce viral excretion. The formulation is designed for non‑invasive intranasal administration, enabling simple, needle‑free delivery. By using a stable protein antigen combined with a muco‑adhesive excipient, the vaccine can be stored at ambient temperatures, facilitating distribution in warm climates. Clinical Phase I demonstrated excellent tolerability, and Phase II aims to confirm superior nasal mucosal immune responses, supporting broader protection across diverse populations.
Target Audience
Primary customers are public health agencies, vaccine manufacturers, and global health organizations seeking scalable, non‑invasive vaccines for respiratory diseases, especially in regions with limited cold‑chain infrastructure.
Features
- Intranasal delivery platform that induces local mucosal immunity to prevent infection and transmission
- Protein‑based antigen design intended for universal vaccine applicability across multiple pathogens
- Needle‑free, user‑friendly administration suitable for all age groups
- Formulation stable at positive (room) temperature, reducing cold‑chain requirements
- Muco‑excipient technology enhancing antigen retention and immune activation in the nasal cavity